212 related articles for article (PubMed ID: 26913960)
1. Molecular basis and current strategies of therapeutic arginine depletion for cancer.
Fultang L; Vardon A; De Santo C; Mussai F
Int J Cancer; 2016 Aug; 139(3):501-9. PubMed ID: 26913960
[TBL] [Abstract][Full Text] [Related]
2. Arginine deprivation in cancer therapy.
Feun LG; Kuo MT; Savaraj N
Curr Opin Clin Nutr Metab Care; 2015 Jan; 18(1):78-82. PubMed ID: 25474015
[TBL] [Abstract][Full Text] [Related]
3. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
4. Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination.
Zhang Y; Chung SF; Tam SY; Leung YC; Guan X
Cancer Lett; 2021 Apr; 502():58-70. PubMed ID: 33429005
[TBL] [Abstract][Full Text] [Related]
5. Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment.
Chu YD; Lai MW; Yeh CT
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445845
[TBL] [Abstract][Full Text] [Related]
6. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
7. Arginine metabolism and deprivation in cancer therapy.
Zou S; Wang X; Liu P; Ke C; Xu S
Biomed Pharmacother; 2019 Oct; 118():109210. PubMed ID: 31330440
[TBL] [Abstract][Full Text] [Related]
8. Arginine-Depleting Enzymes - An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies.
Riess C; Shokraie F; Classen CF; Kreikemeyer B; Fiedler T; Junghanss C; Maletzki C
Cell Physiol Biochem; 2018; 51(2):854-870. PubMed ID: 30466103
[TBL] [Abstract][Full Text] [Related]
9. Recombinant arginine-degrading enzymes in metabolic anticancer therapy and bioanalytics.
Stasyk OV; Boretsky YR; Gonchar MV; Sibirny AA
Cell Biol Int; 2015 Mar; 39(3):246-52. PubMed ID: 25231409
[TBL] [Abstract][Full Text] [Related]
10. Arginine Deiminase: Current Understanding and Applications.
Zarei M; Rahbar MR; Morowvat MH; Nezafat N; Negahdaripour M; Berenjian A; Ghasemi Y
Recent Pat Biotechnol; 2019; 13(2):124-136. PubMed ID: 30569861
[TBL] [Abstract][Full Text] [Related]
11. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.
Kumari N; Bansal S
Cancer Chemother Pharmacol; 2021 Oct; 88(4):565-594. PubMed ID: 34309734
[TBL] [Abstract][Full Text] [Related]
12. Arginine dependence of tumor cells: targeting a chink in cancer's armor.
Patil MD; Bhaumik J; Babykutty S; Banerjee UC; Fukumura D
Oncogene; 2016 Sep; 35(38):4957-72. PubMed ID: 27109103
[TBL] [Abstract][Full Text] [Related]
13. Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents.
Wheatley DN
Anticancer Drugs; 2004 Oct; 15(9):825-33. PubMed ID: 15457122
[TBL] [Abstract][Full Text] [Related]
14. Pegylated arginine deiminase: a novel anticancer enzyme agent.
Feun L; Savaraj N
Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
16. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
Alexandrou C; Al-Aqbi SS; Higgins JA; Boyle W; Karmokar A; Andreadi C; Luo JL; Moore DA; Viskaduraki M; Blades M; Murray GI; Howells LM; Thomas A; Brown K; Cheng PN; Rufini A
Sci Rep; 2018 Aug; 8(1):12096. PubMed ID: 30108309
[TBL] [Abstract][Full Text] [Related]
18. Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Shen LJ; Shen WC
Curr Opin Mol Ther; 2006 Jun; 8(3):240-8. PubMed ID: 16774044
[TBL] [Abstract][Full Text] [Related]
19. Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.
Somani RR; Chaskar PK
Mini Rev Med Chem; 2018; 18(4):363-368. PubMed ID: 27538511
[TBL] [Abstract][Full Text] [Related]
20. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
